KR950700069A - 염증성 피부병의 치료방법(Methods of treating inflammatory dermatoses) - Google Patents

염증성 피부병의 치료방법(Methods of treating inflammatory dermatoses)

Info

Publication number
KR950700069A
KR950700069A KR1019940702690A KR19940702690A KR950700069A KR 950700069 A KR950700069 A KR 950700069A KR 1019940702690 A KR1019940702690 A KR 1019940702690A KR 19940702690 A KR19940702690 A KR 19940702690A KR 950700069 A KR950700069 A KR 950700069A
Authority
KR
South Korea
Prior art keywords
acid
tetramethyl
tetrahydro
naphthalenyl
corticosteroid
Prior art date
Application number
KR1019940702690A
Other languages
English (en)
Other versions
KR100282575B1 (ko
Inventor
엠. 클릭만 알버트
Original Assignee
엠. 클릭만 알버트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엠. 클릭만 알버트 filed Critical 엠. 클릭만 알버트
Publication of KR950700069A publication Critical patent/KR950700069A/ko
Application granted granted Critical
Publication of KR100282575B1 publication Critical patent/KR100282575B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

염증성 피부병은 코티코스테로이드 및 레티노이드를 둘 다 함유하는 조성물을 감염된 피부 부위에 국부적으로 적용함으로써 억제 및 치료된다. 혼합 요법은 어떠한 활성 성분 단독의 요법보다 더욱 효과적이며 코티코스테로이드 단독 치료에 내성이 있거나 생겨난 만성 피부병에 특히 효과적이다. 코티코스테로이드-레티노이드 조성물을 1일 1 또는 2회 적용하여 치료한 후, 통상적으로 수주후에는 치료되는 특정 피부병에 따라, 조성물의 적용의 빈도를 줄이거나 농도를 낮춤으로써 또는 코티코스테로이드 또는 레티노이드중 단지하나, 효능이 약한 코티코스테로이드 또는 다른 비-스테로이드성 요법을 적용함으로써 치료 상태를 유지할수 있다.

Description

염증성 피부병의 치료방법(Methods of treating inflammatory dermatoses)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 건선을 제외한 염증성 피부병을 억제하고 치료하는데 유용한 양으로 코티코스테로이드 및 레티노이드를 포함하는 조성물을 감염된 피부 부위에 국부적으로 투여함을 특징으로 하여, 건선을 제외한 염증성 피부병을 억제하고 치료하는 방법.
  2. 제1항에 있어서, 피부병이 염증성 심상성 좌창, 심한 염증성 집족성 좌창, 편평 태선, 원판상 흥반성루푸스, 원형 탈모증, 가성 모낭염, 모공성 흥색 비강진, 용상 진균증, 염증성 주사비, 만성 아토피성 피부염, 만성 접촉성 피부염, 만성 손피부염 및 급성 약물 반응으로 이루어진 그룹으로부터 선택되는 방법.
  3. 제1항에 있어서, 코티코스테로이드가 조성물 중에 약 0.00001 내지 3중량%의 양으로 존재하는 방법.
  4. 제1항에 있어서, 레티노이드가 조성물 중에 약 0.0001 내지 1중량%의 트레티노인에 상당하는 양으로 존재하는 방법.
  5. 제1항에 있어서, 상기 조성물을 피부병이 억제 및 치료될 때까지 1일 1 또는 2회 피부에 적용하고, 그 이후 치료 상태가 조성물 또는 코티코스테로이드 또는 레티노이드 단독의 적용 빈도를 줄이거나 농도를 낮춤으로써 유지되는 방법.
  6. 제5항에 있어서, 적용 빈도의 감소가 코티코스테로이드 주당 약 수회 적용 또는 레티노이드 1일 약 1회 적용을 포함하는 방법.
  7. 제1항에 있어서, 코티코스테로이드가 그룹 I 내지 그룹 V의 효능 코티코스테로이드인 방법.
  8. 제7항에 있어서, 코티코스테로이드가 베타메타손 발레레이트, 트리암시놀론 아세토나이드 및 클로베타솔 프로피오네이트로 이루어진 그룹으로부터 선택되는 방법.
  9. 제1항에 있어서, 레티노이드가 트레티노인인 방법.
  10. 제1항에 있어서, 상기 조성물이 트레티노인을 약 0.05 내지 0.1중량% 및 베타메타손 발레레이트, 트리암시놀론 아세토나이드 및 클로베타솔 프로피오네이트로 이루어진 그룹으로부터 선택되는 코티코스테로이드를 약 0.05 내지 약 0.1중량% 포함하는 방법.
  11. 제1항에 있어서, 레티노이드가 전(全)-트란스-레티노산, 13-시스-레타노산, 11-시스-레티노산, 9-시스-레티노산, 레티놀, 레티날,(전-E)-9-(4-메톡시-2,3,6-트리메틸페닐)-3,7-디메틸-2,4,6,8-노나테트라에노산 에틸에스테르, (전-E)-9-(4-메톡시-2,3,6-트리메틸페닐)-3,7-디메틸-2,4,6,8-노나테트라에노산, N-에틸-9-(4-메톡시-2,3,6-트리메틸페닐)-3,7-디메틸-2,4,6,8-노나테트라엔아미드, (E,E)-9-(2,6-디클로로-4-메톡시-3-메틸-페닐)-3,7-디메틸-2,4,6,8-노나테트라에노산 에틸에스테르, 7,8-디데하이드로레티노산, (E,E)-4-[2-메틸-4-(2,6,6-트리메틸-1-사이클로헥센-1-일)-1,3-부타디에닐]벤조산, (E)-4-[4-메틸-6-(2,6,6-트리메틸-1-사이클로헥센-1-일)-1,3,5-헥사트리에닐]벤조산, (전-E)-3,7-디메틸-3-티에닐)-2,4,6,8-노나테트라에노산,(E,E,E)-3-메틸-7-(5,6,7,8-테트라하이드로-5,5,8,8-테트라메틸-2-나프탈레닐)-2,4,6-옥타트리에노산,(E)-6-[2-(2,6,6-트리메틸-1-사이클로헥센-1-일)에테닐]-2-나프탈렌 카복실산, (E,E,E)-7-(2,3-디하이드로-1,1,3,3-테트라메틸-1H-인덴-5-일)-3-메틸-2,4,6-옥타트리에노산, (E)-4-[2-(2,3-디하이드로-1,1,3,3-테트라메틸-1H-인덴-5-일)-1-프로페닐]벤조산, (E)-4-[2-(5,6,7,8-테트라하이드로-5,5,8,8-테트라메틸-2-나프탈레닐-1-프로페닐]벤조산, (E)-4-[2-(5,6,7,8-테트라하이드로-3-메틸-5,5,8,8-테트라메틸-2-나프탈레닐-1-프로페닐]벤조산, (E)-1,2,3,4-테트라하이드로-1,1,4,4-테트라메틸-6-(1-메틸-2-페닐에테닐)-나프탈렌, 6-(1,2,3,4-테트라하이드로-1,1,3,4-테트라메틸-6-나프틸)-2-나프탈렌카복실산, (E)-6-[2-(4-(에틸설포닐)페닐]-1-메틸에테닐]-1,2,3,4-테트라하이드로-1,1,4,4-테트라메틸나프탈렌, 4-[(5,6,7,8-테트라하이드로-5,5,8,8-테트라메틸-2-나프탈레닐)에티닐]벤조산, (E)-2-(1,1,4,4-테트라메틸-1,2,3,4-테트라하이드로나프트-7-일-1-[4-테트라졸-5-일)페닐]-1-프로펜, (E)-4-[2-(5,6,7,8-테트라하이드로-7-하이드록시-5,5,8,8-테트라메틸-2-나프탈레닐)-1-프로페닐]벤질 알콜, 레티노일 팔미테이트, 레티닐 팔미테이트, 레티닐 프로피오네이트, (6-(3-(1-아다만틸)-4-메톡시페닐)-2-나프토산, 11-시스-, 13-시스-12-하이드록시 메틸레티노산-락톤, 4-아세트아미도페닐 레티노에이트, 1-(4-카복시페닐)-4-(5,6,7,8-테트라하이드로-5,5,8,8-테트라메틸-2-나프탈레닐)피라졸, 1-(4-카복시페닐)-5-하이드록시-3-(5,6,7,8-테트라하이드로-5,5,8,8-테트라메틸-2-나프탈레닐)피라졸, 4-[(5,6,7,8-테트라하이드로-5,5,8,8-테트라메틸-2-나프탈레닐)-에티닐]메틸설포닐벤젠, 레티노일-글루쿠로나이드, 4-[(5,6,7,8-테트라하이드로-5,5,8,8-테트라메틸-2-나프탈레닐)카바모일]벤조산, 및 4-[(5,6,7,8-테트라하이드로-5,5,8,8-테트라메틸-2-나프탈레닐)카복스아미도]벤조산으로 이루어진 그룹으로부터 선택되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940702690A 1992-02-07 1993-01-29 염증성 피부병치료용 약제학적 조성물 KR100282575B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83282892A 1992-02-07 1992-02-07
US07/832,828 1992-02-07
US7/832.828 1992-02-07
PCT/US1993/001043 WO1993015740A1 (en) 1992-02-07 1993-01-29 Methods of treating inflammatory dermatoses

Publications (2)

Publication Number Publication Date
KR950700069A true KR950700069A (ko) 1995-01-16
KR100282575B1 KR100282575B1 (ko) 2001-02-15

Family

ID=25262717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702690A KR100282575B1 (ko) 1992-02-07 1993-01-29 염증성 피부병치료용 약제학적 조성물

Country Status (12)

Country Link
US (1) US5998395A (ko)
EP (1) EP0625045A4 (ko)
JP (1) JP2927961B2 (ko)
KR (1) KR100282575B1 (ko)
AU (1) AU667519B2 (ko)
CA (1) CA2129114A1 (ko)
CZ (1) CZ188394A3 (ko)
FI (1) FI943625A (ko)
NO (1) NO942913L (ko)
NZ (1) NZ249379A (ko)
WO (1) WO1993015740A1 (ko)
ZA (1) ZA93811B (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659080B1 (en) * 1992-09-11 2001-07-11 BROWN, Sandra Method for the treatment of hair loss
US6344448B1 (en) 1992-09-11 2002-02-05 Stb Family Limited Partnership Composition for the treatment of hair loss
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
AU5728596A (en) * 1995-05-05 1996-11-21 Mark S. Braiman Treatment of psoriasis with 11-cis-retinoic acid
US6008254A (en) * 1997-05-09 1999-12-28 Kligman; Douglas E. Method of treating skin disorders with high-strength tretinoin
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
EP1025857A4 (en) * 1997-10-22 2003-11-12 Eisai Co Ltd RETINOIC ACID AGONISTS, PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITES
FR2761600B1 (fr) 1998-06-19 2000-03-31 Oreal Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
FR2804323B1 (fr) * 2000-01-31 2006-07-07 Galderma Res & Dev Utilisation de composes de type retinoides en tant qu'agents anti-bacteriens
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US20050003023A1 (en) * 2002-06-28 2005-01-06 Meisner Lorraine Faxon Topical composition for the treatment of psoriasis and related skin disorders
ATE402692T1 (de) * 2000-05-09 2008-08-15 Kaneka Corp Dermale zusammenstellungen die als wirkstoff coenzym q enthalten
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
KR20020027198A (ko) * 2000-10-02 2002-04-13 차알스 제이. 메츠 염증과 홍반의 완화방법
FR2823117A1 (fr) * 2000-11-14 2002-10-11 Pharmascience Lab Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans
WO2002071025A2 (en) * 2001-03-02 2002-09-12 Spectra Systems Corporation Combinatorial chemistry and compound identification system
ES2188426B1 (es) * 2001-12-12 2004-11-16 Rosalia Pidal Fernandez Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
US20030199488A1 (en) * 2002-04-23 2003-10-23 Trotta Gina M. Treatment of hyperproliferative disorders/inflammatory dermatoses
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
US8232304B2 (en) * 2002-10-24 2012-07-31 G & R Pharmaceuticals, Llc Antifungal formulations
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
ATE497763T1 (de) * 2003-11-21 2011-02-15 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
NZ549159A (en) * 2004-02-19 2011-01-28 Chemaphor Inc Topical formulations for the treatment of skin conditions
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
KR101327590B1 (ko) 2004-09-28 2013-11-12 체마폴, 인코포레이티드. 체중 증가 및 사료 전환을 촉진하는 조성물 및 방법
US20070009607A1 (en) * 2005-07-11 2007-01-11 George Jones Antibacterial/anti-infalmmatory composition and method
AU2008316225B2 (en) 2007-10-26 2014-06-19 Avivagen Inc. Compositions and methods for enhancing immune response
ES2327201B1 (es) 2008-04-23 2010-07-23 Ignacio Umbert Millet Composicion farmaceutica personalizada para el rejuvenecimiento de la piel que contiene acido retinoico.
CA2975313C (en) 2009-04-30 2020-06-30 Avivagen Inc. Methods and compositions for improving the health of animals
EP2490542A4 (en) 2009-10-20 2015-12-30 Discovery Partners Llc DERMATOLOGICAL AND COSMETIC COMPOSITIONS
ES2378028B1 (es) 2012-02-22 2013-02-18 Ignacio Umbert Millet Composición cosmética para el rejuvenecimiento de la piel y procedimiento y usos correspondientes
KR20200060459A (ko) * 2017-09-28 2020-05-29 존슨 앤드 존슨 컨수머 인코포레이티드 화장 조성물 및 피부 치료 방법
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729568A (en) * 1969-09-23 1973-04-24 Johnson & Johnson Acne treatment
US4126693A (en) * 1975-11-03 1978-11-21 Johnson & Johnson Retinoic acid derivatives in the treatment of acne
ZA77678B (en) * 1977-02-07 1978-09-27 S Fourie Pharmaceutical composition and use thereof
US4487782A (en) * 1982-03-26 1984-12-11 Ortho Pharmaceutical Corporation Topical treatment of non-inflammatory acne
US4889847A (en) * 1986-11-03 1989-12-26 Ortho Pharmaceutical Corporation Prevention of glucocorticoid-induced skin atrophy
US5019569A (en) * 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy

Also Published As

Publication number Publication date
EP0625045A4 (en) 1995-01-18
NO942913D0 (ko) 1994-08-05
AU3585493A (en) 1993-09-03
NZ249379A (en) 1998-07-28
KR100282575B1 (ko) 2001-02-15
CZ188394A3 (en) 1996-02-14
WO1993015740A1 (en) 1993-08-19
FI943625A0 (fi) 1994-08-04
JPH07505617A (ja) 1995-06-22
US5998395A (en) 1999-12-07
AU667519B2 (en) 1996-03-28
CA2129114A1 (en) 1993-08-19
EP0625045A1 (en) 1994-11-23
FI943625A (fi) 1994-08-04
NO942913L (no) 1994-10-05
JP2927961B2 (ja) 1999-07-28
ZA93811B (en) 1993-09-10

Similar Documents

Publication Publication Date Title
KR950700069A (ko) 염증성 피부병의 치료방법(Methods of treating inflammatory dermatoses)
US4889847A (en) Prevention of glucocorticoid-induced skin atrophy
Beckenbach et al. Retinoid treatment of skin diseases
Zouboulis Retinoids–which dermatological indications will benefit in the near future?
KR880701548A (ko) 레티노이드로 일광 손상된 인체 피부를 치료하는 방법
US5019569A (en) Reversal of glucocorticoid-induced skin atrophy
Thielitz et al. Topical retinoids in acne vulgaris: update on efficacy and safety
CA2104452C (en) Treatment of cellulite with retinoids
Shalita et al. Effects of tazarotene 0.1% cream in the treatment of facial acnevulgaris: Pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials
US5468495A (en) Methods of preventing and reducing the size of Striae distensae lesions
Karadag et al. The Background of Retinoids
CONS Retinol, Retinyl Esters, and Retinoic Acid
Tatliparmak et al. Management of Vitamin A and Retinoid Side Effects
Ertekin et al. Mechanism of Action of Topical Retinoids
Rademaker et al. Retinoids in Rosacea
Arsiwala Chemical peels for melasma
NZ286443A (en) Treatment of inflammatory dermatoses other than psoriasis using a retinoid and a corticosteroid
KR900011448A (ko) 레티노이드를 사용하여 자연적으로 노화된 피부를 치료 또는 예방하는 방법
ALBAYRAK Exploring the Therapeutic Potential and Practical Considerations of Retinoids in Dermatological Practice
Gold Novel AHA-Retinoid Ester in Combination with Salicylic Acid for the Treatment of Acne

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee